Fludarabine was used to treat 68 patients with previously treated chronic lymphocytic leukemia (CLL). Nine (13%) patients achieved a complete remission and 30 (44%) a partial remission. The response rates for Rai stages 0 to 2, 3, and 4 were 64%, 58%, and 50% respectively. Seventeen (43%) of the 40 Rai stage 1 to 3 patients and four (19%) of the Rai stage 4 patients returned to Rai stage 0. Survival was strongly correlated with the final Rai stage achieved. The survival of the 11 partial responders with residual disease consisting only of residual bone-marrow nodules was similar to the complete responders (36+ months) and superior to the other partial response patients (16 months). The response to fludarabine was rapid, with 36 (92%) of the 39 responders having achieved at least a partial response following the first three courses. Complete responses occurred in the blood, liver, spleen, and lymph nodes in 48% to 69% of the patients. Eradication of all disease in the bone marrow occurred in only 13% of the cases. Neutropenia and thrombocytopenia occurred in 56% and 25% of evaluable courses. Major infections occurred in 9% of evaluable courses and fevers of unknown origin or minor infections in 12% of courses respectively. Myelosuppression and infection were more common in patients with initial Rai stages 3 and 4 and in nonresponding patients. Other toxicity was mild. No CNS toxicity was noted.
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia
- Share Icon Share
- Tools Icon Tools
- Search Site
- PDF LinkPDF
MJ Keating, H Kantarjian, M Talpaz, J Redman, C Koller, B Barlogie, W Velasquez, W Plunkett, EJ Freireich, KB McCredie; Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74 (1): 19–25. doi: https://doi.org/10.1182/blood.V74.1.19.bloodjournal74119
Download citation file: